Tolvaptan for treating autosomal dominant polycystic kidney disease

Equality Impact Assessment (Guidance development) (PDF 172 KB)

Appeal decision (PDF 109 KB)

Appeal decision (PDF 212 KB)

Appeal decision (PDF 21 KB)

Final appraisal determination information

Final appraisal determination document (PDF 435 KB)

Committee papers information

Committee papers (PDF 4.27 MB)

Appraisal consultation

Appraisal consultation document (PDF 160 KB)

Committee papers information

Committee papers (PDF 6.6 MB)

Equality impact assessment - scoping (PDF 64 KB)

Response to consultee and commentator comments (PDF 448 KB)

Final matrix (PDF 39 KB)

Final scope (PDF 98 KB)

Kidney disease (autosomal dominant polycystic - tolvaptan: draft scope for consultation (pre-referral) - June 2013 (PDF 61 KB)

Kidney disease (autosomal dominant polycystic) - tolvaptan: provisional matrix (pre-referral) - April 2012 (PDF 36 KB)